Logo.jpg
Biofrontera AG: Conference call to discuss third quarter 2021 financial results to be held on November 18, 2021
November 09, 2021 05:45 ET | Biofrontera AG
Leverkusen, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Logo.jpg
Biofrontera announces preliminary revenue for Q1 2021
April 08, 2021 10:30 ET | Biofrontera AG
Leverkusen, Germany, April 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported...
Logo.jpg
Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
February 26, 2021 09:20 ET | Biofrontera AG
Leverkusen, Germany, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company,...
Logo.jpg
Biofrontera AG: Receives reasons from the Federal Court of Justice for overturning ruling of the Cologne Higher Regional Court
October 14, 2020 04:30 ET | Biofrontera AG
Leverkusen, Germany, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, had announced on...
Logo.jpg
Admission to trading of Biofrontera’s 1.00% qualified subordinated mandatory convertible bond 2020/2021
August 20, 2020 13:00 ET | Biofrontera AG
Leverkusen, Germany, Aug. 20, 2020 (GLOBE NEWSWIRE) -- On August 18, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE 00 6046113) announced the successful placement of the 1.00% qualified...
Logo.jpg
Capital measure oversubscribed: Placement of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021
August 18, 2020 05:00 ET | Biofrontera AG
Leverkusen, Germany, Aug. 18, 2020 (GLOBE NEWSWIRE) -- In a press release dated July 27, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced the issuance of up to 2,638,150...
Logo.jpg
Supervisory Board of Biofrontera AG renews Management Board appointment
July 23, 2020 08:30 ET | Biofrontera AG
Leverkusen, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today...
logo.jpg
Biofrontera confirms financing need
June 30, 2020 08:30 ET | Biofrontera AG
Leverkusen, Germany, June 30, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today confirmed the...
logo.jpg
Biofrontera announces conference call to be held on April 21, 2020 to discuss full year 2019 financial results
April 09, 2020 12:30 ET | Biofrontera AG
Leverkusen, Germany, April 09, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing...
logo.jpg
European Medicines Agency recommends indication expansion of Ameluz® for treatment of actinic keratoses on the extremities and trunk/neck
February 03, 2020 05:45 ET | Biofrontera AG
Leverkusen, Germany, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that...